The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Over The 2026–2030 Period?

The market for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS) has experienced significant expansion over recent years. This market is projected to expand from $5.97 billion in 2025 to $6.41 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.3%. Historically, this expansion has been driven by factors such as the scarcity of specific complement therapies, challenges in diagnosis owing to the rarity of these conditions, the dependence on plasma exchange alongside supportive care, the prohibitive costs of treatment that limit access, and a general lack of understanding regarding complement-mediated disorders.

The paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market size is anticipated to experience substantial growth over the next few years, projected to reach $8.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period is propelled by the development of next-generation complement inhibitors, increasing diagnosis rates through advanced testing methods, a heightened focus on orphan disease drug development, expanded reimbursement coverage for rare diseases, and the growing establishment of specialty hematology and nephrology centers. Key trends for the forecast period include the rising adoption of complement inhibitor therapies, increased utilization of genetic and biomarker testing, the proliferation of long-acting complement inhibition drugs, the expansion of specialized rare disease treatment centers, and improved early diagnosis of complement-mediated disorders.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24357&type=smp

Which Major Factors Are Driving The Expansion Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?

The increasing occurrence of rare diseases is anticipated to boost the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market in the future. These conditions, categorized as rare diseases, impact a small segment of the populace, generally involving fewer than 200,000 individuals, and are frequently marked by their intricate nature, seriousness, and the necessity for specialized medical care. This growing incidence of rare diseases stems from improvements in diagnostic tools, facilitating enhanced detection and recognition of conditions that were previously either underreported or not diagnosed. Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) play a role in advancing the comprehension and management of rare diseases, offering valuable insights into their underlying disease mechanisms (pathophysiology) and identifying possible therapeutic targets for conditions where treatment options are scarce. As an illustration, in November 2024, data from the US-based federal agency, the Food and Drug Administration, indicated that over 7,000 rare diseases affected more than 30 million people within the United States. Consequently, the increasing occurrence of rare diseases is fueling the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market.

How Is The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Segmented Across Key Categories?

The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market covered in this report is segmented –

1) By Type: Soliris, Ultomiris

2) By Disease Type: Paroxysmal Nocturnal Hemoglobinuria(PNH), Atypical Hemolytic Uremic Syndrome(aHUS)

3) By Treatment Type: Complement Inhibitors, Plasma Exchange Or Infusion, Other Symptomatic Treatments

4) By Diagnosis Method: Clinical Diagnosis, Genetic Testing, Biomarker Testing

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Soliris: Eculizumab For PNH, Eculizumab For aHUS, Eculizumab Biosimilars

2) By Ultomiris: Ravulizumab For PNH, Ravulizumab For aHUS, Ravulizumab Extended-Interval Dosing

Which Trends Are Impacting The Growth Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?

Leading companies in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market are concentrating on creating innovative products, such as complement inhibitors, to enhance treatment outcomes and patient convenience. Complement inhibitors are therapeutic agents designed to block specific components of the complement system, which is a part of the immune system that aids in clearing pathogens and damaged cells. For example, in December 2023, Novartis AG, a pharmaceutical company based in Switzerland, obtained U.S. Food and Drug Administration (FDA) approval for Fabhalta (iptacopan). This product is the first oral monotherapy for treating adults with paroxysmal nocturnal hemoglobinuria and offers superior hemoglobin improvement without requiring transfusions. This innovative complement inhibitor operates by inhibiting Factor B in the alternative complement pathway, providing extensive control over both intravascular and extravascular hemolysis. Its oral administration simplifies disease management and elevates the quality of life for patients, alleviating the burdens associated with frequent infusions.

Who Are The Dominant Players Shaping The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Landscape?

Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market are Roche Holding AG, Alexion Pharmaceuticals Inc, Genentech Inc, Novartis AG, Apellis Pharmaceuticals Inc, Omeros Corporation, BioCryst Pharmaceuticals Inc, ChemoCentryx Inc, Sanofi SA, CSL Behring, Takeda Pharmaceutical Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Horizon Therapeutics, Achillion Pharmaceuticals Inc, Sobi Swedish Orphan Biovitrum AB, ImmunoForge Co Ltd, Care Pharma, Daiichi Sankyo Co Ltd, Astellas Pharma Inc, Mallinckrodt Pharmaceuticals, CANbridge Pharmaceuticals Inc.

Read the full paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market report here:

https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-and-atypical-hemolytic-uremic-syndrome-ahus-global-market-report

Which Region Currently Holds The Largest Share Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24357&type=smp

Browse Through More Reports Similar to the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market 2026, By The Business Research Company

Hemoglobin Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/hemoglobin-testing-global-market-report

Hemodialysis Global Market Report

https://www.thebusinessresearchcompany.com/report/hemodialysis-global-market-report

Hemoglobinopathies Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/hemoglobinopathies-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model